All Stories

  1. Increased In Vivo Exposure of N-(4-Hydroxyphenyl) Retinamide (4-HPR) to Achieve Plasma Concentrations Effective against Dengue Virus

    Article • Pharmaceutics, July 2023, MDPI AG

    Christopher Porter

  2. Introducing the Molecular Pharmaceutics Special Issue on “Emerging Trends in Molecular Pharmaceutics across Australasia”

    Article • Molecular Pharmaceutics, April 2023, American Chemical Society (ACS)

    Christopher Porter

  3. Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid

    Article • Molecular Pharmaceutics, March 2023, American Chemical Society (ACS)

    Christopher Porter

  4. Intra-articular Injection of a B Cell Depletion Antibody Enhances Local Exposure to the Joint-Draining Lymph Node in Mice with Collagen-Induced Arthritis

    Article • Molecular Pharmaceutics, March 2023, American Chemical Society (ACS)

    Christopher Porter

  5. Obesity-associated mesenteric lymph leakage impairs the trafficking of lipids, lipophilic drugs and antigens from the intestine to mesenteric lymph nodes

    Article • European Journal of Pharmaceutics and Biopharmaceutics, November 2022, Elsevier

    Christopher Porter

  6. Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport

    Article • Frontiers in Pharmacology, September 2022, Frontiers

    Christopher Porter

  7. Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma

    Article • Journal of Controlled Release, August 2022, Elsevier

    Christopher Porter

  8. Biocompatible Cationic Lipoamino Acids as Counterions for Oral Administration of API-Ionic Liquids

    Article • Pharmaceutical Research, June 2022, Springer Science + Business Media

    Christopher Porter

  9. Polymeric Nanotubes as Drug Delivery Vectors─Comparison of Covalently and Supramolecularly Assembled Constructs

    Article • Biomacromolecules, May 2022, American Chemical Society (ACS)

    Christopher Porter

  10. Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport

    Article • Frontiers in Pharmacology, April 2022, Frontiers

    Christopher Porter

  11. Intra-articular injection of biologic anti-rheumatic drugs enhances local exposure to the joint-draining lymphatics

    Article • European Journal of Pharmaceutics and Biopharmaceutics, April 2022, Elsevier

    Christopher Porter

  12. Association of a vaccine adjuvant with endogenous HDL increases lymph uptake and dendritic cell activation

    Article • European Journal of Pharmaceutics and Biopharmaceutics, March 2022, Elsevier

    Christopher Porter

  13. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport

    Article • Journal of Controlled Release, January 2022, Elsevier

    Christopher Porter

  14. Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity

    Article • Nature Metabolism, September 2021, Springer Science + Business Media

    Christopher Porter

  15. Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations

    Article • Pharmaceutical Research, September 2021, Springer Science + Business Media

    Christopher Porter

  16. Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles

    Article • Pharmaceutical Research, August 2021, Springer Science + Business Media

    Christopher Porter

  17. Quantitatively Tracking Bio–Nano Interactions of Metal–Phenolic Nanocapsules by Mass Cytometry

    Article • ACS Applied Materials & Interfaces, July 2021, American Chemical Society (ACS)

    Christopher Porter

  18. Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide

    Article • Pharmaceutical Research, June 2021, Springer Science + Business Media

    Christopher Porter

  19. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network

    Article • Advanced Drug Delivery Reviews, April 2021, Elsevier

    Christopher Porter

  20. Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice

    Article • Journal of Controlled Release, April 2021, Elsevier

    Christopher Porter

  21. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability

    Article • Molecular Pharmaceutics, March 2021, American Chemical Society (ACS)

    Christopher Porter

  22. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs

    Article • Journal of Controlled Release, March 2021, Elsevier

    Christopher Porter

  23. Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat

    Article • International Journal of Pharmaceutics, March 2021, Elsevier

    Christopher Porter

  24. Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations

    Article • International Journal of Pharmaceutics, March 2021, Elsevier

    Christopher Porter

  25. Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration

    Article • Nanomedicine, February 2021, Future Medicine

    Christopher Porter

  26. A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes

    Article • Journal of Biological Chemistry, January 2021, Elsevier

    Christopher Porter

  27. The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs

    Article • Journal of Pharmaceutical Sciences, January 2021, Elsevier

    Christopher Porter

  28. High-Density Lipoprotein Composition Influences Lymphatic Transport after Subcutaneous Administration

    Article • Molecular Pharmaceutics, June 2020, American Chemical Society (ACS)

    Christopher Porter

  29. Targeting immune cells within lymph nodes

    Article • Nature Nanotechnology, June 2020, Springer Science + Business Media

    Christopher Porter

  30. Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans

    Article • Frontiers in Physiology, May 2020, Frontiers

    Christopher Porter

  31. Spatial Properties of Reactive Oxygen Species Govern Pathogen-Specific Immune System Responses

    Article • Antioxidants & Redox Signaling, May 2020, Mary Ann Liebert Inc

    Christopher Porter

  32. Organ-specific lymphatics play distinct roles in regulating HDL trafficking and composition

    Article • AJP Gastrointestinal and Liver Physiology, April 2020, American Physiological Society

    Christopher Porter

  33. Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations

    Article • Pharmaceutical Research, February 2020, Springer Science + Business Media

    Christopher Porter

  34. API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility

    Article • RSC Advances, January 2020, Royal Society of Chemistry

    Christopher Porter

  35. Lymph-directed immunotherapy – Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer

    Article • Advanced Drug Delivery Reviews, January 2020, Elsevier

    Christopher Porter

  36. Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure

    Article • Pharmaceutics, December 2019, MDPI AG

    Christopher Porter

  37. Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats

    Article • Journal of Controlled Release, December 2019, Elsevier

    Christopher Porter

  38. Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties

    Article • Molecular Pharmaceutics, November 2019, American Chemical Society (ACS)

    Christopher Porter

  39. Engineering Biocoatings To Prolong Drug Release from Supraparticles

    Article • Biomacromolecules, August 2019, American Chemical Society (ACS)

    Christopher Porter

  40. The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group

    Article • European Journal of Pharmaceutical Sciences, June 2019, Elsevier

    Christopher Porter

  41. A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats

    Article • European Journal of Pharmaceutics and Biopharmaceutics, April 2019, Elsevier

    Christopher Porter

  42. A ligand-induced structural change in fatty acid–binding protein 1 is associated with potentiation of peroxisome proliferator–activated receptor α agonists

    Article • Journal of Biological Chemistry, March 2019, Elsevier

    Christopher Porter

  43. Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms

    Article • Advanced Drug Delivery Reviews, March 2019, Elsevier

    Christopher Porter

  44. Pointing in the Right Direction: Controlling the Orientation of Proteins on Nanoparticles Improves Targeting Efficiency

    Article • Nano Letters, February 2019, American Chemical Society (ACS)

    Christopher Porter

  45. Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation

    Article • Journal of Controlled Release, February 2019, Elsevier

    Christopher Porter

  46. A Nonionic Polyethylene Oxide (PEO) Surfactant Model: Experimental and Molecular Dynamics Studies of Kolliphor EL

    Article • Journal of Pharmaceutical Sciences, January 2019, Elsevier

    Christopher Porter

  47. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations

    Article • Molecular Pharmaceutics, October 2018, American Chemical Society (ACS)

    Christopher Porter

  48. Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery

    Article • ACS Applied Materials & Interfaces, September 2018, American Chemical Society (ACS)

    Christopher Porter

  49. Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistribution

    Article • Biomaterials, September 2018, Elsevier

    Christopher Porter

  50. Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats

    Article • Journal of Pharmaceutical Sciences, September 2018, Elsevier

    Christopher Porter

  51. Minimum information reporting in bio–nano experimental literature

    Article • Nature Nanotechnology, September 2018, Springer Science + Business Media

    Christopher Porter

  52. Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations

    Article • Molecular Pharmaceutics, August 2018, American Chemical Society (ACS)

    Christopher Porter

  53. Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker

    Article • Molecular Pharmaceutics, August 2018, American Chemical Society (ACS)

    Christopher Porter

  54. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome

    Article • Proceedings of the National Academy of Sciences, July 2018, Proceedings of the National Academy of Sciences

    Christopher Porter

  55. Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels

    Article • Journal of Neurochemistry, July 2018, Wiley

    Professor Philip John Marriott, Christopher Porter

  56. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation

    Article • Molecular Pharmaceutics, May 2018, American Chemical Society (ACS)

    Christopher Porter

  57. Fatty Acid–Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells

    Article • Journal of Pharmaceutical Sciences, April 2018, Elsevier

    Professor Martin J Scanlon, Christopher Porter

  58. Lipids in the Stomach – Implications for the Evaluation of Food Effects on Oral Drug Absorption

    Article • Pharmaceutical Research, February 2018, Springer Science + Business Media

    Christopher Porter

  59. Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations

    Article • Journal of Pharmaceutical Sciences, January 2018, Elsevier

    Christopher Porter

  60. Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets

    Article • Journal of Neurochemistry, December 2017, Wiley

    Professor Philip John Marriott, Dr Kwok Ho Christopher Choy, Christopher Porter

  61. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623

    Article • Molecular Pharmaceutics, November 2017, American Chemical Society (ACS)

    Christopher Porter

  62. Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site

    Article • Nanomedicine Nanotechnology Biology and Medicine, November 2017, Elsevier

    Christopher Porter

  63. Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

    Article • Proceedings of the National Academy of Sciences, October 2017, Proceedings of the National Academy of Sciences

    Christopher Porter

  64. Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies

    Article • Molecular Pharmaceutics, October 2017, American Chemical Society (ACS)

    Christopher Porter

  65. Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids

    Article • Molecular Pharmaceutics, October 2017, American Chemical Society (ACS)

    Christopher Porter

  66. Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers

    Article • European Journal of Pharmaceutics and Biopharmaceutics, October 2017, Elsevier

    Christopher Porter

  67. Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution

    Article • ACS Applied Materials & Interfaces, September 2017, American Chemical Society (ACS)

    Christopher Porter

  68. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration

    Article • Biomacromolecules, August 2017, American Chemical Society (ACS)

    Christopher Porter

  69. Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

    Article • Nature Communications, July 2017, Nature

    Christopher Porter

  70. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief

    Article • Science Translational Medicine, May 2017, American Association for the Advancement of Science

    Christopher Porter, Professor Martin J Scanlon

  71. Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids

    Article • Molecular Pharmaceutics, February 2017, American Chemical Society (ACS)

    Christopher Porter

  72. Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion

    Article • Molecular Pharmaceutics, February 2017, American Chemical Society (ACS)

    Christopher Porter

  73. Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods

    Article • Molecular Pharmaceutics, January 2017, American Chemical Society (ACS)

    Christopher Porter

  74. Fatty Acid-Binding Protein 5 at the Blood–Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function

    Article • Journal of Neuroscience, November 2016, Society for Neuroscience

    Christopher Porter, Professor Martin J Scanlon, Dr Kwok Ho Christopher Choy

  75. Frontispiece: Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie, October 2016, Wiley

    Christopher Porter

  76. Frontispiz: Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie, October 2016, Wiley

    Christopher Porter

  77. Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs

    Article • Molecular Pharmaceutics, September 2016, American Chemical Society (ACS)

    Christopher Porter

  78. Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals

    Article • Pharmaceutical Research, August 2016, Springer Science + Business Media

    Christopher Porter

  79. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie, August 2016, Wiley

    Christopher Porter

  80. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie, August 2016, Wiley

    Christopher Porter

  81. Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation

    Article • Molecular Pharmaceutics, June 2016, American Chemical Society (ACS)

    Christopher Porter

  82. 50years of oral lipid-based formulations: Provenance, progress and future perspectives

    Article • Advanced Drug Delivery Reviews, June 2016, Elsevier

    Christopher Porter

  83. Computational prediction of formulation strategies for beyond-rule-of-5 compounds

    Article • Advanced Drug Delivery Reviews, June 2016, Elsevier

    Christopher Porter

  84. Understanding the Challenge of Beyond-Rule-of-5 Compounds

    Article • Advanced Drug Delivery Reviews, June 2016, Elsevier

    Christopher Porter

  85. Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab′ Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity

    Article • Molecular Pharmaceutics, April 2016, American Chemical Society (ACS)

    Christopher Porter

  86. Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug

    Article • Journal of Pharmaceutical Sciences, February 2016, Elsevier

    Christopher Porter

  87. Tools for Early Prediction of Drug Loading in Lipid-Based Formulations

    Article • Molecular Pharmaceutics, January 2016, American Chemical Society (ACS)

    Christopher Porter

  88. Passive tumour targeting and extravasation of cylindrical polymer brushes in mouse xenografts

    Article • Chemical Communications, January 2016, Royal Society of Chemistry

    Christopher Porter

  89. The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats

    Article • Journal of Pharmaceutical Sciences, January 2016, Elsevier

    Christopher Porter

  90. A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations

    Article • Pharmaceutical Research, December 2015, Springer Science + Business Media

    Christopher Porter

  91. Fatty Acid-Binding Protein 5 Facilitates the Blood–Brain Barrier Transport of Docosahexaenoic Acid

    Article • Molecular Pharmaceutics, December 2015, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  92. Pluronic-Functionalized Silica–Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases

    Article • Molecular Pharmaceutics, December 2015, American Chemical Society (ACS)

    Christopher Porter

  93. Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers

    Article • Nanomedicine Nanotechnology Biology and Medicine, November 2015, Elsevier

    Christopher Porter

  94. A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep

    Article • Pharmaceutical Research, October 2015, Springer Science + Business Media

    Christopher Porter

  95. From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity

    Article • Nature Reviews Drug Discovery, October 2015, Nature

    Christopher Porter

  96. Fatty Acid Binding Proteins Expressed at the Human Blood–Brain Barrier Bind Drugs in an Isoform-Specific Manner

    Article • Pharmaceutical Research, August 2015, Springer Science + Business Media

    Christopher Porter, Professor Martin J Scanlon

  97. Transformation of Poorly Water-Soluble Drugs into Lipophilic Ionic Liquids Enhances Oral Drug Exposure from Lipid Based Formulations

    Article • Molecular Pharmaceutics, May 2015, American Chemical Society (ACS)

    Christopher Porter

  98. Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor α in a Ligand-selective Manner

    Article • Journal of Biological Chemistry, April 2015, American Society for Biochemistry & Molecular Biology (ASBMB)

    Christopher Porter, Professor Martin J Scanlon

  99. Optimal PEGylation can Improve the Exposure of Interferon in the Lungs Following Pulmonary Administration

    Article • Journal of Pharmaceutical Sciences, April 2015, Elsevier

    Christopher Porter

  100. The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport

    Article • Journal of Visualized Experiments, March 2015, MyJove Corporation

    Christopher Porter

  101. Size and Rigidity of Cylindrical Polymer Brushes Dictate Long Circulating PropertiesIn Vivo

    Article • ACS Nano, February 2015, American Chemical Society (ACS)

    Christopher Porter

  102. PEGylation Does Not Significantly Change the Initial Intravenous or Subcutaneous Pharmacokinetics or Lymphatic Exposure of Trastuzumab in Rats but Increases Plasma Clearance after Subcutaneous Administration

    Article • Molecular Pharmaceutics, February 2015, American Chemical Society (ACS)

    Christopher Porter

  103. Methotrexate-Conjugated PEGylated Dendrimers Show Differential Patterns of Deposition and Activity in Tumor-Burdened Lymph Nodes after Intravenous and Subcutaneous Administration in Rats

    Article • Molecular Pharmaceutics, February 2015, American Chemical Society (ACS)

    Christopher Porter

  104. Profiling the Role of Deacylation-Reacylation in the Lymphatic Transport of a Triglyceride-Mimetic Prodrug

    Article • Pharmaceutical Research, December 2014, Springer Science + Business Media

    Christopher Porter

  105. An in Vitro Digestion Test That Reflects Rat Intestinal Conditions To Probe the Importance of Formulation Digestion vs First Pass Metabolism in Danazol Bioavailability from Lipid Based Formulations

    Article • Molecular Pharmaceutics, November 2014, American Chemical Society (ACS)

    Christopher Porter

  106. In vitro–in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623

    Article • European Journal of Pharmaceutics and Biopharmaceutics, November 2014, Elsevier

    Christopher Porter

  107. Nano-chemotherapeutics: Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers

    Article • Journal of Controlled Release, November 2014, Elsevier

    Christopher Porter

  108. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations. 5. Lipolysis of Representative Formulations by Gastric Lipase

    Article • Pharmaceutical Research, October 2014, Springer Science + Business Media

    Christopher Porter

  109. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 6: Effects of Varying Pancreatin and Calcium Levels

    Article • The AAPS Journal, October 2014, Springer Science + Business Media

    Christopher Porter

  110. ‘Stealth’ lipid-based formulations: Poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug

    Article • Journal of Controlled Release, October 2014, Elsevier

    Christopher Porter

  111. Characterization of Two Distinct Modes of Drug Binding to Human Intestinal Fatty Acid Binding Protein

    Article • ACS Chemical Biology, September 2014, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  112. Digestion of Phospholipids after Secretion of Bile into the Duodenum Changes the Phase Behavior of Bile Components

    Article • Molecular Pharmaceutics, August 2014, American Chemical Society (ACS)

    Christopher Porter

  113. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 4: Proposing a New Lipid Formulation Performance Classification System

    Article • Journal of Pharmaceutical Sciences, August 2014, Elsevier

    Christopher Porter

  114. Lipid-Based Formulations Solidified Via Adsorption onto the Mesoporous Carrier Neusilin® US2: Effect of Drug Type and Formulation Composition on In Vitro Pharmaceutical Performance

    Article • Journal of Pharmaceutical Sciences, June 2014, Elsevier

    Christopher Porter

  115. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy

    Article • Journal of Controlled Release, June 2014, Elsevier

    Christopher Porter

  116. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol

    Article • Journal of Pharmacy and Pharmacology, May 2014, Wiley

    Christopher Porter

  117. Choice of Nonionic Surfactant Used to Formulate Type IIIA Self-Emulsifying Drug Delivery Systems and the Physicochemical Properties of the Drug Have a Pronounced Influence on the Degree of Drug Supersaturation that Develops During In Vitro Digestion

    Article • Journal of Pharmaceutical Sciences, April 2014, Elsevier

    Christopher Porter

  118. Targeted delivery of a model immunomodulator to the lymphatic system: Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies

    Article • Journal of Controlled Release, March 2014, Elsevier

    Christopher Porter

  119. Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration

    Article • Antimicrobial Agents and Chemotherapy, February 2014, ASM Journals

    Dr Kashyap Patel, Professor Roger L Nation, Christopher Porter

  120. The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats

    Article • Molecular Pharmaceutics, February 2014, American Chemical Society (ACS)

    Christopher Porter

  121. Non-linear Increases in Danazol Exposure with Dose in Older vs. Younger Beagle Dogs: The Potential Role of Differences in Bile Salt Concentration, Thermodynamic Activity, and Formulation Digestion

    Article • Pharmaceutical Research, January 2014, Springer Science + Business Media

    Christopher Porter

  122. Ionic liquids provide unique opportunities for oral drug delivery: structure optimization and in vivo evidence of utility

    Article • Chemical Communications, January 2014, Royal Society of Chemistry

    Christopher Porter

  123. Gastric Pre-Processing Is an Important Determinant of the Ability of Medium-Chain Lipid Solution Formulations to Enhance Oral Bioavailability in Rats

    Article • Journal of Pharmaceutical Sciences, November 2013, Elsevier

    Christopher Porter

  124. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin

    Article • Journal of Controlled Release, November 2013, Elsevier

    Christopher Porter

  125. Recent Advances in Lipid-Based Formulation Technology

    Article • Pharmaceutical Research, October 2013, Springer Science + Business Media

    Christopher Porter

  126. Population Pharmacokinetics of Colistin Methanesulfonate in Rats: Achieving Sustained Lung Concentrations of Colistin for Targeting Respiratory Infections

    Article • Antimicrobial Agents and Chemotherapy, August 2013, ASM Journals

    Dr Kashyap Patel, Christopher Porter

  127. Evaluation of the Structural Determinants of Polymeric Precipitation Inhibitors Using Solvent Shift Methods and Principle Component Analysis

    Article • Molecular Pharmaceutics, August 2013, American Chemical Society (ACS)

    Christopher Porter

  128. Pulmonary Administration of PEGylated Polylysine Dendrimers: Absorption from the Lung versus Retention within the Lung Is Highly Size-Dependent

    Article • Molecular Pharmaceutics, August 2013, American Chemical Society (ACS)

    Christopher Porter

  129. Lipid-Based Formulations and Drug Supersaturation: Harnessing the Unique Benefits of the Lipid Digestion/Absorption Pathway

    Article • Pharmaceutical Research, July 2013, Springer Science + Business Media

    Christopher Porter

  130. The Potential for Drug Supersaturation during Intestinal Processing of Lipid-Based Formulations May Be Enhanced for Basic Drugs

    Article • Molecular Pharmaceutics, July 2013, American Chemical Society (ACS)

    Christopher Porter

  131. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine

    Article • European Journal of Pharmaceutical Sciences, July 2013, Elsevier

    Christopher Porter

  132. The Impact of Lymphatic Transport on the Systemic Disposition of Lipophilic Drugs

    Article • Journal of Pharmaceutical Sciences, July 2013, Elsevier

    Christopher Porter

  133. Lipid Absorption Triggers Drug Supersaturation at the Intestinal Unstirred Water Layer and Promotes Drug Absorption from Mixed Micelles

    Article • Pharmaceutical Research, June 2013, Springer Science + Business Media

    Christopher Porter

  134. Computational Prediction of Drug Solubility in Lipid Based Formulation Excipients

    Article • Pharmaceutical Research, June 2013, Springer Science + Business Media

    Christopher Porter

  135. A Simple Quantitative Approach for the Determination of Long and Medium Chain Lipids in Bio-relevant Matrices by High Performance Liquid Chromatography with Refractive Index Detection

    Article • AAPS PharmSciTech, June 2013, American Association of Pharmaceutical Scientists (AAPS)

    Christopher Porter

  136. PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

    Article • Journal of Controlled Release, June 2013, Elsevier

    Christopher Porter

  137. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations

    Article • Pharmaceutical Research, May 2013, Springer Science + Business Media

    Christopher Porter

  138. Intestinal Bile Secretion Promotes Drug Absorption from Lipid Colloidal Phases via Induction of Supersaturation

    Article • Molecular Pharmaceutics, May 2013, American Chemical Society (ACS)

    Christopher Porter

  139. Silica–lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation

    Article • Journal of Controlled Release, April 2013, Elsevier

    Christopher Porter

  140. A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport

    Article • Pharmaceutical Research, February 2013, Springer Science + Business Media

    Christopher Porter

  141. The Effect of Administered Dose of Lipid-Based Formulations on the In Vitro and In Vivo Performance of Cinnarizine as a Model Poorly Water-Soluble Drug

    Article • Journal of Pharmaceutical Sciences, February 2013, Elsevier

    Christopher Porter

  142. In vitro digestion testing of lipid-based delivery systems: Calcium ions combine with fatty acids liberated from triglyceride rich lipid solutions to form soaps and reduce the solubilization capacity of colloidal digestion products

    Article • International Journal of Pharmaceutics, January 2013, Elsevier

    Christopher Porter

  143. Strategies to Address Low Drug Solubility in Discovery and Development

    Article • Pharmacological Reviews, January 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  144. Toward the Establishment of Standardizedin VitroTests for Lipid-Based Formulations. 2. The Effect of Bile Salt Concentration and Drug Loading on the Performance of Type I, II, IIIA, IIIB, and IV Formulations duringin VitroDigestion

    Article • Molecular Pharmaceutics, November 2012, American Chemical Society (ACS)

    Christopher Porter

  145. Incomplete Desorption of Liquid Excipients Reduces thein Vitroandin VivoPerformance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier

    Article • Molecular Pharmaceutics, September 2012, American Chemical Society (ACS)

    Christopher Porter

  146. Intravenous Dosing Conditions May Affect Systemic Clearance for Highly Lipophilic Drugs: Implications for Lymphatic Transport and Absolute Bioavailability Studies

    Article • Journal of Pharmaceutical Sciences, September 2012, Elsevier

    Christopher Porter

  147. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 1: Method Parameterization and Comparison of In Vitro Digestion Profiles Across a Range of Representative Formulations

    Article • Journal of Pharmaceutical Sciences, September 2012, Elsevier

    Christopher Porter

  148. Lipid Digestion as a Trigger for Supersaturation: Evaluation of the Impact of Supersaturation Stabilization on the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems

    Article • Molecular Pharmaceutics, June 2012, American Chemical Society (ACS)

    Christopher Porter

  149. Association of Chemotherapeutic Drugs with Dendrimer Nanocarriers: An Assessment of the Merits of Covalent Conjugation Compared to Noncovalent Encapsulation

    Article • Molecular Pharmaceutics, March 2012, American Chemical Society (ACS)

    Christopher Porter

  150. Doxorubicin-Conjugated PEGylated Dendrimers Show Similar Tumoricidal Activity but Lower Systemic Toxicity When Compared to PEGylated Liposome and Solution Formulations in Mouse and Rat Tumor Models

    Article • Molecular Pharmaceutics, March 2012, American Chemical Society (ACS)

    Christopher Porter

  151. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems

    Article • Nanomedicine Nanotechnology Biology and Medicine, January 2012, Elsevier

    Christopher Porter

  152. Corrigendum

    Article • Nanomedicine, January 2012, Future Medicine

    Christopher Porter

  153. Correction to “Targeted Drug Delivery to Lymphocytes: A Route to Site-Specific Immunomodulation?”

    Article • Molecular Pharmaceutics, December 2011, American Chemical Society (ACS)

    Christopher Porter

  154. Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration

    Article • Drug Delivery and Translational Research, November 2011, Springer Science + Business Media

    Christopher Porter

  155. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance

    Article • Journal of Pharmaceutical Sciences, November 2011, Elsevier

    Christopher Porter

  156. Targeting the lymphatics using dendritic polymers (dendrimers)

    Article • Advanced Drug Delivery Reviews, September 2011, Elsevier

    Christopher Porter

  157. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties

    Article • Nanomedicine, August 2011, Future Medicine

    Christopher Porter

  158. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration

    Article • Journal of Controlled Release, July 2011, Elsevier

    Christopher Porter

  159. Acute Hypertriglyceridemia Promotes Intestinal Lymphatic Lipid and Drug Transport: A Positive Feedback Mechanism in Lipid and Drug Absorption

    Article • Molecular Pharmaceutics, June 2011, American Chemical Society (ACS)

    Christopher Porter

  160. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker

    Article • Journal of Controlled Release, June 2011, Elsevier

    Christopher Porter

  161. Fatty Acid Binding Proteins: Potential Chaperones of Cytosolic Drug Transport in the Enterocyte?

    Article • Pharmaceutical Research, April 2011, Springer Science + Business Media

    Christopher Porter, Professor Martin J Scanlon

  162. Capping Methotrexate α-Carboxyl Groups Enhances Systemic Exposure and Retains the Cytotoxicity of Drug Conjugated PEGylated Polylysine Dendrimers

    Article • Molecular Pharmaceutics, April 2011, American Chemical Society (ACS)

    Christopher Porter

  163. Preparation, crystallization and preliminary X-ray diffraction analysis of two intestinal fatty-acid binding proteins in the presence of 11-(dansylamino)undecanoic acid

    Article • Acta Crystallographica Section F Structural Biology and Crystallization Communications, January 2011, International Union of Crystallography

    Christopher Porter, Professor Martin J Scanlon

  164. Targeted Drug Delivery to Lymphocytes: A Route to Site-Specific Immunomodulation?

    Article • Molecular Pharmaceutics, December 2010, American Chemical Society (ACS)

    Christopher Porter

  165. Crystallizing Membrane Proteins for Structure Determination using Lipidic Mesophases

    Article • Journal of Visualized Experiments, November 2010, MyJove Corporation

    Christopher Porter

  166. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility

    Article • Journal of Drug Targeting, October 2010, Informa Healthcare

    Christopher Porter

  167. The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) and Evaluation of Their Impact on Lymph Lipoprotein Profiles

    Article • Pharmaceutical Research, July 2010, Springer Science + Business Media

    Christopher Porter

  168. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media

    Article • Journal of Pharmacy and Pharmacology, June 2010, Royal Pharmaceutical Society (Pharmaceutical Press)

    Christopher Porter

  169. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation

    Article • Journal of Pharmacy and Pharmacology, June 2010, Royal Pharmaceutical Society (Pharmaceutical Press)

    Christopher Porter

  170. The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623)

    Article • Pharmaceutical Research, March 2010, Springer Science + Business Media

    Christopher Porter

  171. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats

    Article • Journal of Controlled Release, December 2009, Elsevier

    Christopher Porter

  172. Partly-PEGylated Poly-L-lysine Dendrimers Have Reduced Plasma Stability and Circulation Times Compared With Fully PEGylated Dendrimers

    Article • Journal of Pharmaceutical Sciences, October 2009, Elsevier

    Christopher Porter

  173. Probing the Fibrate Binding Specificity of Rat Liver Fatty Acid Binding Protein

    Article • Journal of Medicinal Chemistry, September 2009, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  174. Lymphatic Transport of Methylnortestosterone Undecanoate (MU) and the Bioavailability of Methylnortestosterone Are Highly Sensitive to the Mass of Coadministered Lipid after Oral Administration of MU

    Article • Journal of Pharmacology and Experimental Therapeutics, August 2009, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  175. Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-l-lysine Dendrimers

    Article • Molecular Pharmaceutics, August 2009, American Chemical Society (ACS)

    Christopher Porter

  176. Oral Bioavailability Assessment and Intestinal Lymphatic Transport of Org 45697 and Org 46035, Two Highly Lipophilic Novel Immunomodulator Analogues

    Article • Current Drug Delivery, August 2009, Bentham Science Publishers

    Christopher Porter

  177. Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism

    Article • Pharmaceutical Research, March 2009, Springer Science + Business Media

    Christopher Porter

  178. Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein

    Article • Molecular and Cellular Biochemistry, January 2009, Springer Science + Business Media

    Christopher Porter, Professor Martin J Scanlon

  179. An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity

    Article • Journal of Pharmacy and Pharmacology, October 2008, Wiley

    Christopher Porter

  180. An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity

    Article • Journal of Pharmacy and Pharmacology, October 2008, Oxford University Press (OUP)

    Christopher Porter

  181. Characterization of the Drug Binding Specificity of Rat Liver Fatty Acid Binding Protein

    Article • Journal of Medicinal Chemistry, July 2008, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  182. The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Polyl-Lysine Dendrimers

    Article • Molecular Pharmaceutics, June 2008, American Chemical Society (ACS)

    Christopher Porter

  183. Enhancing intestinal drug solubilisation using lipid-based delivery systems

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  184. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  185. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  186. Lipid-based systems for the enhanced delivery of poorly water soluble drugs

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  187. Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs

    Article • Journal of Pharmaceutical Sciences, February 2008, Elsevier

    Christopher Porter

  188. Use of plasma proteins as solubilizing agents in in vitro permeability experiments: Correction for unbound drug concentration using the reciprocal permeability approach

    Article • Journal of Pharmaceutical Sciences, January 2008, Elsevier

    Christopher Porter

  189. Impact of Surface Derivatization of Poly-l-lysine Dendrimers with Anionic Arylsulfonate or Succinate Groups on Intravenous Pharmacokinetics and Disposition

    Article • Molecular Pharmaceutics, December 2007, American Chemical Society (ACS)

    Christopher Porter

  190. Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model

    Article • Drug Metabolism and Disposition, September 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  191. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats

    Article • International Journal of Pharmaceutics, August 2007, Elsevier

    Christopher Porter

  192. Low Dose Lipid Formulations: Effects on Gastric Emptying and Biliary Secretion

    Article • Pharmaceutical Research, July 2007, Springer Science + Business Media

    Christopher Porter

  193. Examination of the Role of Intestinal Fatty Acid-Binding Protein in Drug Absorption Using a Parallel Artificial Membrane Permeability Assay

    Article • Chemistry & Biology, April 2007, Elsevier

    Christopher Porter, Professor Martin J Scanlon

  194. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs

    Article • Nature Reviews Drug Discovery, March 2007, Nature

    Christopher Porter

  195. Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs

    Article • Pharmaceutical Research, February 2007, Springer Science + Business Media

    Christopher Porter

  196. Impact of Cremophor-EL and Polysorbate-80 on Digoxin Permeability across Rat Jejunum: Delineation of Thermodynamic and Transporter Related Events Using the Reciprocal Permeability Approach

    Article • Journal of Pharmaceutical Sciences, February 2007, Elsevier

    Christopher Porter

  197. Cationic Poly-l-lysine Dendrimers:  Pharmacokinetics, Biodistribution, and Evidence for Metabolism and Bioresorption after Intravenous Administration to Rats

    Article • Molecular Pharmaceutics, October 2006, American Chemical Society (ACS)

    Christopher Porter

  198. Permeability assessment of poorly water‐soluble compounds under solubilizing conditions: The reciprocal permeability approach

    Article • Journal of Pharmaceutical Sciences, October 2006, Elsevier

    Christopher Porter

  199. Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacylglycerols

    Article • European Journal of Lipid Science and Technology, September 2006, Wiley

    Dr Rene Holm, Christopher Porter

  200. The Absorption of Darbepoetin Alfa Occurs Predominantly via the Lymphatics Following Subcutaneous Administration to Sheep

    Article • Pharmaceutical Research, August 2006, Springer Science + Business Media

    Christopher Porter

  201. An Acute and Coincident Increase in FABP Expression and Lymphatic Lipid and Drug Transport Occurs During Intestinal Infusion of Lipid-Based Drug Formulations to Rats

    Article • Pharmaceutical Research, July 2006, Springer Science + Business Media

    Christopher Porter

  202. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone

    Article • Journal of Pharmacy and Pharmacology, June 2006, Wiley

    Christopher Porter

  203. AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT

    Article • Drug Metabolism and Disposition, February 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  204. An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli

    Article • Protein Expression and Purification, November 2005, Elsevier

    Christopher Porter, Professor Martin J Scanlon

  205. The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport

    Article • Journal of Pharmacology and Experimental Therapeutics, October 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  206. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire® core

    Article • Journal of Controlled Release, October 2005, Elsevier

    Christopher Porter

  207. Tissue uptake of DDT is independent of chylomicron metabolism

    Article • Archives of Toxicology, September 2005, Springer Science + Business Media

    Christopher Porter

  208. Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat

    Article • Pharmaceutical Research, August 2005, Springer Science + Business Media

    Christopher Porter

  209. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water‐soluble drug

    Article • Journal of Pharmaceutical Sciences, March 2005, Elsevier

    Christopher Porter

  210. Subcutaneous drug delivery and the role of the lymphatics

    Article • Drug Discovery Today Technologies, March 2005, Elsevier

    Christopher Porter

  211. The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein

    Article • Journal of Biological Chemistry, February 2005, American Society for Biochemistry & Molecular Biology (ASBMB)

    Christopher Porter, Professor Martin J Scanlon

  212. Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2005, De Gruyter

    Christopher Porter

  213. Lymphatic Absorption Is the Primary Contributor to the Systemic Availability of Epoetin Alfa following Subcutaneous Administration to Sheep

    Article • Journal of Pharmacology and Experimental Therapeutics, December 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  214. A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs

    Article • Journal of Controlled Release, September 2004, Elsevier

    Christopher Porter

  215. Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation

    Article • Pharmaceutical Research, August 2004, Springer Science + Business Media

    Christopher Porter

  216. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine

    Article • Journal of Pharmaceutical Sciences, May 2004, Elsevier

    Christopher Porter

  217. Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins

    Article • Journal of Controlled Release, March 2004, Elsevier

    Christopher Porter

  218. Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  219. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid‐based delivery systems: A phase diagram approach

    Article • Journal of Pharmaceutical Sciences, February 2004, Elsevier

    Christopher Porter

  220. Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations

    Article • Pharmaceutical Research, February 2004, Springer Science + Business Media

    Christopher Porter

  221. Drug Solubilization Behavior During in Vitro Digestion of Suspension Formulations of Poorly Water-Soluble Drugs in Triglyceride Lipids

    Article • Pharmaceutical Research, February 2004, Springer Science + Business Media

    Christopher Porter

  222. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model

    Article • Journal of Pharmacy and Pharmacology, January 2004, Wiley

    Christopher Porter

  223. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides

    Article • European Journal of Pharmaceutical Sciences, September 2003, Elsevier

    Christopher Porter

  224. APPLICATION OF COMPARTMENTAL MODELING TO AN EXAMINATION OF IN VITRO INTESTINAL PERMEABILITY DATA: ASSESSING THE IMPACT OF TISSUE UPTAKE, P-GLYCOPROTEIN, AND CYP3A

    Article • Drug Metabolism and Disposition, August 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  225. Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  226. Using the Polymer Partitioning Method to Probe the Thermodynamic Activity of Poorly Water‐soluble Drugs Solubilized in Model Lipid Digestion Products

    Article • Journal of Pharmaceutical Sciences, June 2003, Elsevier

    Christopher Porter

  227. Separation and Characterization of the Colloidal Phases Produced on Digestion of Common Formulation Lipids and Assessment of Their Impact on the Apparent Solubility of Selected Poorly Water-Soluble Drugs

    Article • Journal of Pharmaceutical Sciences, March 2003, Elsevier

    Christopher Porter

  228. Desbutylhalofantrine: Evaluation of QT Prolongation and Other Cardiovascular Effects after Intravenous Administration In Vivo

    Article • Journal of Cardiovascular Pharmacology, March 2003, Wolters Kluwer Health

    Christopher Porter

  229. A Kinetic Evaluation of the Absorption, Efflux, and Metabolism of Verapamil in the Autoperfused Rat Jejunum

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  230. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrineIn Vivo?

    Article • Biopharmaceutics & Drug Disposition, January 2003, Wiley

    Christopher Porter

  231. Article • Pharmaceutical Research, January 2003, Springer Science + Business Media

    Christopher Porter

  232. Article • Pharmaceutical Research, January 2003, Springer Science + Business Media

    Christopher Porter

  233. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine

    Article • AAPS PharmSci, December 2002, Springer Science + Business Media

    Christopher Porter

  234. Effect of dietary fatty acids on the intestinal permeability of marker drug compounds in excised rat jejunum

    Article • Journal of Pharmacy and Pharmacology, June 2002, Oxford University Press (OUP)

    Christopher Porter

  235. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs

    Article • Journal of Pharmaceutical Sciences, March 2002, Elsevier

    Christopher Porter

  236. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products

    Article • Journal of Pharmacy and Pharmacology, January 2002, Oxford University Press (OUP)

    Christopher Porter

  237. Article • Pharmaceutical Research, January 2002, Springer Science + Business Media

    Christopher Porter

  238. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil

    Article • Journal of Pharmacy and Pharmacology, December 2001, Wiley

    Christopher Porter

  239. In vitro assessment of oral lipid based formulations

    Article • Advanced Drug Delivery Reviews, October 2001, Elsevier

    Christopher Porter

  240. A Conscious Dog Model for Assessing the Absorption, Enterocyte‐Based Metabolism, and Intestinal Lymphatic Transport of Halofantrine

    Article • Journal of Pharmaceutical Sciences, October 2001, Elsevier

    Christopher Porter

  241. Animal models for the study of intestinal lymphatic drug transport

    Article • Advanced Drug Delivery Reviews, August 2001, Elsevier

    Christopher Porter

  242. Intestinal lymphatic drug transport: an update

    Article • Advanced Drug Delivery Reviews, August 2001, Elsevier

    Christopher Porter

  243. Lymphatic transport of proteins after s.c. injection: implications of animal model selection

    Article • Advanced Drug Delivery Reviews, August 2001, Elsevier

    Christopher Porter

  244. Transport and absorption of drugs via the lymphatic system

    Article • Advanced Drug Delivery Reviews, August 2001, Elsevier

    Christopher Porter

  245. Lipid-Based Formulations for Oral Administration

    Article • August 2001, Taylor & Francis

    Christopher Porter

  246. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis

    Article • Journal of Pharmaceutical and Biomedical Analysis, June 2001, Elsevier

    Christopher Porter

  247. LIPID-BASED FORMULATIONS FOR ORAL ADMINISTRATION: OPPORTUNITIES FOR BIOAVAILABILITY ENHANCEMENT AND LIPOPROTEIN TARGETING OF LIPOPHILIC DRUGS

    Article • Journal of Receptors and Signal Transduction, January 2001, Taylor & Francis

    Christopher Porter

  248. Article • Pharmaceutical Research, January 2001, Springer Science + Business Media

    Christopher Porter

  249. The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment

    Article • International Journal of Pharmaceutics, September 2000, Elsevier

    Christopher Porter

  250. Effect of Short‐, Medium‐, and Long‐Chain Fatty Acid‐Based Vehicles on the Absolute Oral Bioavailability and Intestinal Lymphatic Transport of Halofantrine and Assessment of Mass Balance in Lymph‐Cannulated and Non‐cannulated Rats

    Article • Journal of Pharmaceutical Sciences, August 2000, Elsevier

    Christopher Porter

  251. Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion

    Article • International Journal of Pharmaceutics, April 2000, Elsevier

    Christopher Porter

  252. Lymphatic Transport of Proteins After Subcutaneous Administration

    Article • Journal of Pharmaceutical Sciences, March 2000, Elsevier

    Christopher Porter

  253. Systemic Availability and Lymphatic Transport of Human Growth Hormone Administered by Subcutaneous Injection

    Article • Journal of Pharmaceutical Sciences, February 2000, Elsevier

    Christopher Porter

  254. Differences in the Lipoprotein Binding profile of Halofantrine in Fed and Fasted Human or beagle Plasma are dictated by the Respective Masses of Core Apolar Lipoprotein Lipid

    Article • Journal of Pharmaceutical Sciences, March 1999, American Geophysical Union (AGU)

    Christopher Porter

  255. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: In vitro studies in normolipidemic and dyslipidemic human plasmas

    Article • Journal of Pharmaceutical Sciences, February 1999, American Geophysical Union (AGU)

    Christopher Porter

  256. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole

    Article • Journal of Pharmaceutical Sciences, December 1998, American Geophysical Union (AGU)

    Christopher Porter

  257. Association of Halofantrine with Postprandially Derived Plasma Lipoproteins Decreases Its Clearance Relative To Administration in the Fasted State

    Article • Journal of Pharmaceutical Sciences, August 1998, American Geophysical Union (AGU)

    Christopher Porter

  258. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine

    Article • International Journal of Pharmaceutics, June 1998, Elsevier

    Christopher Porter

  259. Differences in pre- and post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma

    Article • Journal of Pharmaceutical and Biomedical Analysis, September 1997, Elsevier

    Christopher Porter

  260. Uptake of drugs into the intestinal lymphatics after oral administration

    Article • Advanced Drug Delivery Reviews, April 1997, Elsevier

    Christopher Porter

  261. Physicochemical and Physiological Mechanisms for the Effects of Food on Drug Absorption: The Role of Lipids and pH

    Article • Journal of Pharmaceutical Sciences, March 1997, American Geophysical Union (AGU)

    Christopher Porter

  262. Evaluation of emulsifiable glasses for the oral administration of cyclosporin in beagle dogs

    Article • International Journal of Pharmaceutics, September 1996, Elsevier

    Christopher Porter

  263. Lipophilic prodrugs designed for intestinal lymphatic transport

    Article • Advanced Drug Delivery Reviews, May 1996, Elsevier

    Christopher Porter

  264. A physicochemical Basis for the Effect of Food on the Absolute Oral Bioavailability of Halofantrine

    Article • Journal of Pharmaceutical Sciences, May 1996, American Geophysical Union (AGU)

    Christopher Porter

  265. Lymphatic Transport of Halofantrine in the Conscious Rat When Administered as Either the Free Base or the Hydrochloride Salt: Effect of Lipid Class and Lipid Vehicle Dispersion

    Article • Journal of Pharmaceutical Sciences, April 1996, American Geophysical Union (AGU)

    Christopher Porter

  266. Lymphatic Transport of Halofantrine in the Triple-Cannulated Anesthetized Rat Model: Effect of Lipid Vehicle Dispersion

    Article • Journal of Pharmaceutical Sciences, April 1996, American Geophysical Union (AGU)

    Christopher Porter

  267. Model Systems for Intestinal Lymphatic Transport Studies

    Article • January 1996, Springer Science + Business Media

    Christopher Porter

  268. Synthesis and evaluation of 5′ alkyl ester prodrugs of zidovudine for directed lymphatic delivery

    Article • International Journal of Pharmaceutics, January 1996, Elsevier

    Christopher Porter

  269. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions

    Article • Journal of Pharmaceutical and Biomedical Analysis, March 1995, Elsevier

    Professor Martin J Scanlon, Christopher Porter

  270. Microspheres for targeting drugs to specific body sites

    Article • Journal of Controlled Release, May 1993, Elsevier

    Christopher Porter

  271. The polyoxyethylene/polyoxypropylene block co‐polymer Poloxamer‐407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow

    Article • FEBS Letters, June 1992, Wiley

    Christopher Porter

  272. Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow

    Article • International Journal of Pharmaceutics, June 1992, Elsevier

    Christopher Porter

  273. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating

    Article • Biochemical and Biophysical Research Communications, June 1991, Elsevier

    Christopher Porter

  274. The effect of poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres

    Article • International Journal of Pharmaceutics, February 1991, Elsevier

    Christopher Porter